GV-backed Cambridge Epigenetix lines up $88M to roll out genetic sequencing technology
With the additional funds, the University of Cambridge spinout will accelerate the commercialization of its sequencing platform. It’ll also ramp up manufacturing of the first product built on the platform, which the company said is expected to be commercially available by early next year.